Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company OncoMed Pharmaceuticals Inc.
DescriptionBispecific antibody against delta-like 4 (DLL4) and VEGF
Molecular Target Delta-like 4 (DLL4) ; Vascular endothelial growth factor (VEGF)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced refractory solid tumors; Treat solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today